Extended Screening Costs Associated With Selecting Donors for Fecal Microbiota Transplantation for Treatment of Metabolic Syndrome-Associated Diseases

Laura J Craven, Seema Nair Parvathy, Justin Tat-Ko, Jeremy P Burton, Michael S Silverman, Laura J Craven, Seema Nair Parvathy, Justin Tat-Ko, Jeremy P Burton, Michael S Silverman

Abstract

Background: Knowledge of the impact of the gut microbiome on conditions other than Clostridium difficile infection has been rapidly increasing, and the potential usefulness of fecal microbiota transplantation (FMT) in these indications is being explored. The need to exclude donors with an increased risk of these diseases has left uncertainties regarding the cost and feasibility of donor screening. The aim of this study was to compare our experience to other donor-screening programs and report the costs associated with establishing a donor-screening program, for the treatment of metabolic syndrome-related conditions.

Methods: Forty-six potential donors (PDs) had their medical histories and physical examinations undertaken by a physician. Blood, stool, and urine were screened for 31 viral, bacterial, fungal, and protozoan agents in addition to biochemical characteristics. The price of advertising, doctor's visits and diagnostic tests were calculated to determine the cost of finding a donor.

Results: Of the PDs screened, 5 of 46 passed the history, examination, blood, stool, and urine tests. The most common reasons for exclusion included a body mass index >25 or the detection of Blastocystis hominis, Dientamoeba fragilis, or Helicobacter pylori. Four of five eligible donors had subsequent travel or illness that contraindicated donation, so only 1 of 46 PDs was suitable. The total cost for finding a single suitable donor was $15190 US dollars. This screening was performed in Canada, and costs in the United States would be substantially higher.

Conclusions: New potential therapeutic uses for FMT have created a demand for stricter exclusion criteria for donors. This study illustrates that screening many individuals to find a donor and the subsequent associated costs may make central processing and shipment a more reasonable alternative.

Keywords: fecal microbiota transplant; metabolic syndrome; stool bank.

Figures

Figure 1.
Figure 1.
Potential donor screening outcomes using expanded donor screening methods. ALT, alanine aminotransferase; BMI, body mass index; EBV, Epstein-Barr virus; ESBL, extended spectrum β-lactamase.

References

    1. Kelly CR, Khoruts A, Staley C et al. . Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 2016; 165:609–16.
    1. Jung Lee W, Lattimer LD, Stephen S et al. . Fecal microbiota transplantation: a review of emerging indications beyond relapsing Clostridium difficile toxin colitis. Gastroenterol Hepatol 2015; 11:24–32.
    1. Dunne JL, Triplett EW, Gevers D et al. . The intestinal microbiome in type 1 diabetes. Clin Exp Immunol 2014; 177:30–7.
    1. Tillisch K, Labus J, Kilpatrick L et al. . Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144:1394–401, 1401.e1–4.
    1. Hohmann EL, Ananthakrishnan AN, Deshpande V. Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med 2014; 371:668–75.
    1. Health Canada. Fecal microbiota therpay used in the treatment of Clostridium difficile infection not responsive to conventional therapies. Guidance Document 2015. Available at: . Accessed 22 May 2017
    1. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36:580–5.
    1. Song SJ, Lauber C, Costello EK et al. . Cohabitating family members share microbiota with one another and with their dogs. Elife 2013; 2:e00458. doi: 10.7554/eLife.00458.
    1. Kazerouni A, Burgess K, Burns LJ, Wein LM. Optimal screening and donor management in a public stool bank. Microbiome 2015; 3:75. doi: 10.1186/s40168-015-0140-3.
    1. Paramsothy S, Borody TJ, Lin E et al. . Donor recruitment for fecal microbiota transplantation. Inflamm Bowel Dis 2015; 21:1600–6.
    1. Costello SP, Tucker EC, La Brooy J et al. . Establishing a fecal microbiota transplant service for the treatment of Clostridium difficile infection. Clin Infect Dis 2016; 62:908–14.
    1. Tariq R, Weatherly R, Kammer P et al. . Donor screening experience for fecal microbiota transplantation in patients with recurrent C. difficile infection. J Clin Gastroenterol 2016; doi:10.1097/MCG.0000000000000768.
    1. OpenBiome. Quality and safety program. 2017. Available at: . Accessed 20 September 2017.
    1. van Nood E, Vrieze A, Nieuwdorp M et al. . Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407–15.
    1. Moayyedi P, Surette MG, Kim PT et al. . Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149:102–109.e6.
    1. Malani PN, Rao K. Expanded evidence for frozen fecal microbiota transplantation for Clostridium difficile infection: a fresh take. JAMA 2016; 315:137–8.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir